What's new?
10/07/2018

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
SOFINNOVA PARTNERS
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.
http://www.recormedical.com/

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.
http://www.otsuka.com/en/

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.
http://www.omd.otsuka.com/en/

16/05/2001

EnvoyWorldWide Inc., the leading provider of enterprise application messaging solutions, has secured eight million dollars in second round venture funding, which fully funds the company’s operations. Leading this round of financing is Longworth Venture Partners. Also contributing are previous investors Battery Ventures and Sofinnova Partners. Building on its strong momentum of the past year, EnvoyWorldWide will use the new funds to develop and expand operations, enabling them to provide services that meet the business-critical notification needs of their growing customer base. Jim Savage, partner of Longworth Venture Partners will join the company’s Board of Directors.


“Battery Ventures has built its business by partnering with leaders and our continued investment in EnvoyWorldWide signifies our recognition and support of their dominance in the enterprise application messaging space.” Todd A. Dagres, general partner at Battery Ventures. “Their services represent the next wave of significant business communications technologies, as is evidenced by the caliber of EnvoyWorldWide’s rapidly growing customer base of over 50 corporate customers, including such innovation-driven companies as OAG Worldwide [a member of the Reed Elsevier group], CCBN, FT Interactive Data, Singapore Telecom, TSI Telecommunications [a subsidiary of Verizon], and Electric Insurance Company.” Designed to solve the challenge of reaching professionals in today’s mobile business environment, EnvoyWorldWide’s communications platform provides companies with outbound, one-to-many, actionable communications that enable the worldwide delivery of business-critical messaging, instantly and simultaneously. Messages are delivered via the wired or wireless communications method each recipient prefers — phone, fax, email, pager, SMS, WAP, or other wireless device. EnvoyWorldWide’s messaging solutions are an integral part of helping companies maximize investment in enterprise applications by linking workflow with communications infrastructure.


“The commitment and confidence shown in our technology, people and opportunity by our investors differentiates EnvoyWorldWide within our market and strengthens our leadership position,” Alain Dasté, co-founder and CEO of EnvoyWorldWide. “This investment, made during this challenging funding period, will enable us to exploit a large and growing market opportunity as major corporations recognize the necessity and business value of automated outbound communications solutions.”


“Sofinnova has long recognized EnvoyWorldWide’s vision, strategy and commitment to creating innovative communications solutions serving the world’s wired and wireless professionals,” Olivier Protard, partner, Sofinnova Partners. “We look forward to integrating EnvoyWorldWide into the European business community and leveraging our contacts to help them grow even faster.”


About Battery Ventures: Battery Ventures (www.battery.com) is one of the world’s largest venture capital firms specializing in early stage technology investments. With a team of over 50 experienced professionals, Battery leverages its bandwidth, industry expertise, and capital to actively guide emerging technology companies to category dominance. Since 1983, the firm has invested worldwide in over 130 companies across the communications, software and Internet/e-Business industries. From its offices in Wellesley, MA and San Mateo, CA, the partnership manages over $1.8 billion in committed capital.


About Longworth Venture Partners: Longworth Venture Partners (www.longworth.com) is an active, early-stage technology venture firm that focuses on investments in four sectors–Internet Media, e-Commerce, Enterprise Software and IT Services. Based in the Boston area, Longworth Venture Partners is unique because of the depth of successful operating experience among its investment professionals. Longworth works closely with entrepreneurs to leverage that operating experience and to help guide and accelerate the growth of successful companies. Recent investments include Softricity, Inc., eMaven, Inc., Digital Paper Corporation, Dirig Software, Inc., Canopy International and Roving Software.


About Sofinnova Partners: Based in Paris, the Sofinnova Partners (sofinnova.social-unit.fr) team consists of 7 partners, managing close to 500 million Euros. Sofinnova Partners invests in start-up and early stage companies, both in Information Technologies and Life Sciences. In Information Technologies, Sofinnova Partners was a founding investor in companies such as BVRP, Egide, Multimania, Maximiles and Atomz. Since 1996, Sofinnova Partners has made 50 investments, including 31 as lead investor.


About EnvoyWorldWide: Headquartered in Billerica, Massachusetts, EnvoyWorldWide is the industry leader in solving the challenge of reaching professionals in today’s mobile business environment. Leading companies worldwide are using EnvoyWorldWide’s enterprise application messaging platform to distribute business-critical information to customers, employees, partners and suppliers via each recipient’s preferred method of communication. Organizations use EnvoyXpress, EnvoyWorldWide’s core service, for applications ranging from improved resource scheduling and proactive customer notification to product delivery and logistical support. EnvoyWorldWide’s services help companies slash operating costs, boost productivity, improve competitive advantage, and cultivate customer loyalty.


Visit website http://www.envoyww.com

16/05/2001

EnvoyWorldWide Inc., premier fournisseur de solutions de messagerie d’entreprise, a levé 8 millions de dollars au cours d’un second tour de table, qui lui serviront à financer ses opérations. Longworth Venture Partners est le principal investisseur de la société. Parmi les précédents investisseurs figuraient Battery Ventures et Sofinnova Partners. Forte d’une croissance exceptionnelle au cours de l’exercice précédent, EnvoyWorldWide utilisera ses nouveaux capitaux pour développer et étendre ses activités, ce qui lui permettra de fournir des services répondant aux besoins de ses clients toujours plus nombreux en matière de notification stratégique. Jim Savage, associé au sein de Longworth Venture Partners, rejoindra le Conseil d’administration de la société.


” Battery Ventures a développé ses activités en partenariat avec des leaders du secteur et son investissement à long terme dans EnvoyWorldWide est la preuve de sa reconnaissance et de son soutien vis-à-vis de cette société dominant le marché de la messagerie d’entreprise “. souligne Todd A. Dagres, associé au sein de Battery Ventures. ” Les services d’EnvoyWorldWide constituent la prochaine vague de technologies de télécommunications professionnelles, comme le prouve la clientèle en pleine croissance de la société qui compte plus de 50 entreprises, notamment des sociétés innovantes, telles que OAG Worldwide (qui appartient au groupe Reed Elsevier), CCBN, FT Interactive Data, Singapore Telecom, TSI Telecommunications (filiale de Verizon), et Electric Insurance Company “.


Conçu pour résoudre les problèmes rencontrés en matière de communication avec les professionnels dans un environnement professionnel mobile, la plate-forme de communication d’EnvoyWorldWide propose aux sociétés des solutions de télécommunications sortantes, “one-to-many”, susceptible de faire l’objet d’un recours, qui permettent d’envoyer des messages stratégiques dans le monde entier, instantanément et simultanément. Ces messages sont envoyés via le réseau de communication câblé et sans fil, selon les souhaits de chaque destinataires (téléphone, télécopieur, courrier électronique, pager, messages SMS, WAP ou tout autre appareil sans fil). Les solutions de messagerie d’EnvoyWorldWide font partie intégrante de l’assistance offerte aux sociétés en matière d’optimisation de leurs investissements dans des applications d’entreprise en reliant le workflow à l’infrastructure de communication.


” Cet engagement et cette confiance en notre technologie, nos salariés et l’opportunité qui nous est donnée par nos investisseurs différencient EnvoyWorldWide au sein de ce marché et renforce sa position de leader “, déclare Alain Daste, co-fondateur et directeur général d’EnvoyWorldWide. ” Cet investissement, réalisé au cours de cette période de financement difficile, nous permettra de tirer parti d’opportunités sur un marché très vaste et en plein essor car les grandes entreprises sont conscientes de la nécessité et de la valeur économique de solutions de télécommunications sortantes automatisées “.


” Sofinnova soutient depuis longtemps l’approche d’EnvoyWorldWide, sa stratégie et son engagement en matière de développement de solutions de télécommunications innovantes reliant les professionnels via les réseaux câblés et sans fil “, déclare Olivier Protard, associé au sein de Sofinnova Partners. ” Nous sommes impatients d’intégrer EnvoyWorldWide à notre communauté professionnelle européenne et de tirer parti de nos contacts avec cette société afin de l’aider à se développer plus rapidement “.


À propos de Battery Ventures: Battery Ventures (http://www.battery.com/) est le premier fond de capital risqué spécialisé dans les hautes technologies dans des sociétés à un stade de développement précoce. Avec une équipe de plus de 50 professionnels, Battery tirer parti de sa bande passante, de son savoir-faire et de ses capitaux pour guider les sociétés développant de nouvelles technologies à dominer leur secteur. Depuis 1983, ce fonds a investit dans plus de 130 sociétés réparties dans le monde entier et intervenant dans les secteurs des télécommunications, des logiciels, de l’Internet et du commerce électronique. Depuis ses bureaux de Wellesley (Massachusetts) et de San Mateo (Californie), ce fonds gère plus de 1,8 milliard de capital engagé.


À propos de Longworth Venture Partners: Longworth Venture Partners (http://www.longworth.com/) est un fonds de capital risque spécialisé dans les hautes technologies dans des sociétés à un stade de développement précoce, qui investit dans quatre secteurs : l’Internet, le commerce électronique, les logiciels professionnels et les services informatiques. Domiciliée dans la région de Boston, Longworth Venture Partners est unique en son genre de par ses connaissances approfondies et son expérience des activités réussies dans le cadre de ses investissements. Longworth travaille en étroite collaboration avec des chefs d’entreprises afin de tirer parti de leur expérience, de les guider et d’accélérer la croissance des sociétés en plein essor. Le fonds a récemment investi dans Softricity Inc., eMaven Inc., Digital Paper Corporation, Dirig Software Inc., Canopy International et Roving Software.


À propos de Sofinnova Partners: Domiciliée à Paris, Sofinnova Partners (http://sofinnova.social-unit.fr/) qui regroupe 7 associés et gère près de 500 millions d’euros. Sofinnova Partners investit dans des start-ups et des sociétés à un stade précoce de développement, dans les secteurs de l’informatique et des sciences du vivant. Dans le secteur de l’informatique, Sofinnova Partners a été l’un des investisseurs fondateurs de sociétés, telles que BVRP, Egide, Multimania, Maximiles et Atomz. Depuis 1996, Sofinnova Partners a réalisé 50 investissements, dont 31 en tant qu’investisseur principal.


À propos d’EnvoyWorldWide: Domiciliée à Billerica (Massachusetts), EnvoyWorldWide est le leader du secteur en matière de résolution des problèmes rencontrés en matière de communication avec les professionnels dans un environnement commercial mobile. Les grandes entreprises au niveau mondial utilisent la plate-forme de messagerie d’entreprise d’EnvoyWorldWide pour envoyer des données stratégiques à leurs clients, salariés, associés et fournisseurs en choisissant le mode de réception préféré de chaque destinataire. Les entreprises utilisent EnvoyXpress, service vedette d’EnvoyWorldWide, pour les applications allant de la planification des ressources à la livraison produit et au support logistique en passant par la notification client proactive. Les services d’EnvoyWorldWide aident les entreprises à réduire leurs frais d’exploitation, à améliorer leur productivité, à être plus concurrentielles et à fidéliser leurs clients. Pour plus d’informations sur EnvoyWorldWide, veuillez consulter le site Internet http://www.envoyww.com/.


CONTACTS : – EnvoyWorldWide Nancy Liberman Tél. : 978-670-0023 poste 132 E-mail : nancyl@envoyww.com


Visit website http://www.envoyww.com

09/05/2001

Paris, France, and Louvain-la-Neuve, Belgium, May, 2001-

Diatos S.A., leader in the development of intracellular/intranuclear peptide-based drug delivery for cancer and infectious diseases, and the Université Catholique de Louvain (UCL), announced today a three years agreement covering a major research and development collaboration on tumor activated prodrugs and drug delivery systems combining Diatos and UCL’s proprietary technologies.

The Company will work in close collaboration with Professor André Trouet, a pioneer and leading figure in the field of Tumor Activated Prodrugs (TAP), and his team of the UCL’s Cell Biology Laboratory. Under the terms of the agreement, joint discoveries will be owned by both parties, and Diatos acquires the right for an exclusive worldwide license from UCL on this technology in the field of oncology.

"This agreement builds on the significant amount of intellectual property we have now accumulated at Diatos," said John Tchelingerian, President & CEO of Diatos. "UCL is an international recognized centre of expertise in life siences and applied biomedical research. This collaboration builds on the world class work carried out by Pr Trouet and his team at UCL which demonstrated the feasibility of using TAP technologies as a robust and very promising anti-cancer approach."

Gilles Capart, the CEO of Sopartec, the investment and technology transfer company of UCL, commented: "This is a good example of a very promising strategic alliance between university and industry which will accelerate the successful development of the company while funding front-end basic research with wide applications".

About Diatos Diatos is a product focused company specialized in the treatment of cancer and infectious diseases. The Company’s mission is to develop, partner and commercialize proprietary intracellular / intranuclear drug delivery systems based on the use of cell translocating antibodies and peptides. Diatos has a robust patent portfolio covering its core technology and applications. A spin off from the Institut Pasteur (Paris, France), Diatos was founded early 1999 by renown scientists including Pr. Stratis Avrameas, the inventor of the ELISA technology, and the French venture capital firm Sofinnova Partners.

Diatos proprietary fully human peptide-based vectors can penetrate into living cells and transport large quantities of low and high molecular weight molecules. The vectors are efficient in selectively delivering small molecules, nucleic acids, proteins (including antibodies) and microspheres into the cell cytoplasm and nucleus. The Company is backed by major European and US venture capital funds: Sofinnova Partners (France), GIMV (Belgium), InterWest Partners (USA), Société Générale Asset Management (France), AGF Private Equity (France) and Sopartec (Belgium).

Diatos S.A., 166 Boulevard du Montparnasse, 75014 Paris, France

Contact info: Dr John Tchelingerian, phone +33-6-62 35 01 78, e-mail: jtcheli@attglobal.net

About UCL UCL is one of the largest universities in Belgium, with 20,000 students. The 10 schools and 50 departments cover most disciplines of science, medicine and human sciences and are based in the campuses of Louvain-la-Neuve and Woluwé (Brussels). Research is conducted in 200 units by a staff of 2000 academic and scientific people. UCL has created recently, on its campus of Louvain-la-Neuve, a new Institute of Life Science (ILS) to group and further develop its research activities in molecular and cellular biology. These encompass a wide spectrum of basic research in the microbiological, vegetal and animal fields, which have therapeutic applications in different pathologies such as atherosclerosis, diabetes and cancer. The background technologies include cell culture, in vitro models, cell pharmacology and pharmacokinetics. http://www.ucl.ac.be/

About Sopartec SOPARTEC SA is the technology transfer and investment affiliated with the University of Louvain (UCL). Active since 10 years in providing seed capital to new companies based on the technologies discovered at the university, its charter has been extended in 1999 to include the management of the intellectual property of UCL, including patents, licenses and collaborative research implying technology transfer. The main objective is to promote and support the research function of the university. Its financial resources originate from capital gains made on its investments. Contact info: Gilles Capart, phone +32-10-47 90 54, e-mail: g.capart@auxin.be

02/05/2001

Biolipox, the Stockholm-based biotechnology company, has just closed a financing round of nearly €5 million with investments from the Swedish venture capital fund HealthCap and Paris based Sofinnova Partners. Antoine Papiernik, General Partner with Sofinnova Partners, joins the board of Biolipox.

The company was formed in 2000 by two scientists, Professors Hans-Erik Claesson and Magnus Bjorkholm from the Karolinska Institute, and is specialized in the discovery and development of new therapeutic compounds for use in the treatment of respiratory diseases and other inflammatory pathologies.

Biolipox had received at the time of the company’s formation a first seed investment of €0.6 brought in by HealthCap. The current investment round is expected to finance the company’s research program through the end of 2002. Biolipox is working on a new metabolic pathway of arachidonic acid, one of the most important and efficient of the fatty acids, which are essential components of diet. The two metabolic pathways already identified have resulted in the development of such vital compounds as aspirin, Cox2 or leucotriene inhibitors. Bengt Samuelson, who won the Nobel Prize for Medicine for his work on prostaglandins and leucotrienes whilst in the same department of the Karolinska Institute, and who is currently the chairman of the Nobel Foundation, sits on the company’s board of directors.

This discovery could result in the development of more specific drugs with the potential to become blockbusters in the treatment of asthma and other inflammatory respiratory diseases. The pharmaceutical products market for the treatment of respiratory diseases (in particular asthma) was estimated at USD 8.5 billion in 1999. There is currently a considerable need for the development of new therapeutic compounds to be used for the acute or chronic treatment of asthma sufferers.

"The quality of the investors that are backing the company confirms the view that Biolipox is a good investment opportunity. The close relationship between the company, its managers, and the Karolinska Institute, which is considered a world-leader in respiratory pathologies, is a further illustration of the importance of the project developed by Biolipox" stated Dr Carl-Johan Daalsgard, MD PhD, Chief Executive Officer of Biolipox, who has worked many years at the Karolinska Institute and as a senior manager with the pharmaceuticals group Astra.

According to Antoine Papiernik, General Partner with Sofinnova Partners, "Biolipox has all the characteristics we look for when financing a start-up: a prestigious team from one of the best academic centers in the world, a discovery of fundamental importance with multiple applications, strong intellectual property rights, and solid financial backing capable of seeing the company through to realization of its plans. Biolipox is also our first investment in Sweden. Until now, we have invested successfully in the UK, Italy, Switzerland, Germany, and of course France. Sweden now appears to us as a country where we can create major biopharmaceutical companies. Furthermore, we consider HealthCap as a top-tier investor in Nordic countries. We have previously worked with them in other company boards, and share similar investment strategies"

Sofinnova Partners, based in Paris since 1972, is a venture capital fund specialized in financing high-potential projects at an early stage of their development. Since its formation, it has supported companies in two specific sectors: life sciences and information technology. It is managed by seven partners and associates and has close to FRF 3 billion of funds under management. In the life sciences field, it favors investments related to bio-pharmacy and medical instrumentation and, notably, was a founder-investor in companies such as Genset, Cerep, NicOx, Actelion and NovusPharma. Sofinnova Partners has made 50 investments since 1996, of which 31 as the lead investor.

Contacts:

Antoine Papiernik General Partner Sofinnova Partners 17 rue de Surène 75008 Paris France Tel: 33 1 53 05 41 00 Fax: 33 1 53 05 41 29 Email: apapiernik@sofinnova.fr Web: http://sofinnova.social-unit.fr/
Carl-Johan Dalsgaard, CEO Biolipox AB, c/o Healthcap Sturegatan 34 Stockholm, Sweden Tel: 46 70 975 98 63

Visit website http://www.orexo.com

02/05/2001

Biolipox, société de biotechnologie implantée à Stockholm vient de clôturer un tour de table de près de 5M€ apportés par le fonds de capital risque suédois HealthCap et par Sofinnova Partners. Antoine Papiernik, General Partner de Sofinnova Partners rejoint le conseil d’administration de l’entreprise.

Cette société, créée en 2000 par deux scientifiques, les Professeurs Hans-Erik Claesson et Magnus Bjorkholm, issus du Karolinska Institute, est spécialisée dans la découverte et le développement de nouvelles molécules thérapeutiques dans les maladies respiratoires et d’autres pathologies inflammatoires.

Elle avait, lors de sa création, bénéficié d’un premier financement d’amorçage, d’un montant de €0,6M de la part de HealthCap. Ce nouvel apport de fonds devrait lui permettre de financer ses programmes de recherche jusqu’à la fin de l’année 2002. Biolipox travaille notamment à la mise en évidence d’un nouveau mécanisme métabolique de l’acide arachidonique, un des acides gras les plus importants et les plus efficaces, dont la présence est indispensable dans le régime alimentaire. Les deux voies métaboliques connues à ce jour ont permis de développer des molécules de première importance, comme l’aspirine, les inhibiteurs de Cox2 ou de Leucotriènes. Bengt Samuelson, Prix Nobel de Médecine pour ses travaux sur les Protaglandines et les Leucotriènes dans ce même département du Karolinska Institute et actuellement Président de la Fondation Nobel, siège d’ailleurs au conseil d’administration de l’entreprise.

Cette découverte pourrait donc permettre de développer des médicaments plus spécifiques ayant le potentiel de devenir des " blockbusters " pour l’asthme et d’autres maladies respiratoires inflammatoires. Les produits pharmaceutiques destinés au traitement des affections respiratoires (en particulier l’asthme) représentent un marché annuel estimé à 8,5 milliards de dollars en 1999. Il existe actuellement un besoin considérable pour la mise au point de nouvelles molécules thérapeutiques capables de traiter les patients asthmatiques, en traitement ponctuel ou régulier.

"La qualité des investisseurs qui nous soutiennent aujourd’hui nous conforte dans l’idée que Biolipox constitue aujourd’hui une bonne opportunité d’investissement. La proximité entre l’entreprise, ses équipes et le Karolinska Institute, considéré comme un des meilleurs au monde dans le domaine des pathologies respiratoires, est une illustration supplémentaire du sérieux et de la pérennité du projet développé par Biolipox ", a déclaré le Dr Carl-Johan Daalsgard, MD PhD, Chief Executive Officer de Biolipox, lui-même issu du Karolinska Institute et ancien cadre dans le groupe pharmaceutique Astra.

"Biolipox a toutes les caractéristiques que nous recherchons lorsque nous finançons une start-up: une équipe prestigieuse issue d’un des meilleurs centres académiques au monde, une découverte fondamentale aux applications multiples, une propriété intellectuelle forte, et un tour de table solide pouvant amener l’entreprise jusqu’à la réalisation de son plan", a déclaré Antoine Papiernik, General Partner de Sofinnova Partners. "Biolipox est aussi notre premier investissement en Suède. Nous avions jusqu’à présent investi avec succès en Grande Bretagne, en Italie, en Suisse, en Allemagne, et bien sur en France. La Suède nous semble aujourd’hui être un pays ou l’on peut créer de grandes entreprises de biopharmacie. Healthcap est en outre un investisseur de premier plan dans les pays nordiques, avec lequel nous avons travaillé à plusieurs reprises."

Sofinnova Partners, basée à Paris depuis 1972, est une société de capital-risque spécialisée dans le financement de projets à fort potentiel à un stade précoce de leur développement. Elle soutient depuis son origine des entreprises appartenant à deux secteurs d’activité spécifiques : les sciences de la vie et les technologies de l’information. Elle est managée par 7 partenaires-associés et gère plus de 3 MdF de fonds. Dans le domaine des sciences de la vie, elle privilégie les investissements liés à la biopharmacie et à l’instrumentation médicale et a notamment été investisseur-fondateur dans des entreprises comme Genset, Cerep, NicOx, Actelion et NovusPharma. Depuis 1996, Sofinnova Partners a réalisé 50 investissements dont 31 en tant que chef de file.

Contacts:

Antoine Papiernik General Partner Sofinnova Partners 17 rue de Surène 75008 Paris France Tel: 33 1 53 05 41 00 Fax: 33 1 53 05 41 29 Email: apapiernik@sofinnova.fr Web: sofinnova.social-unit.fr
Carl-Johan Dalsgaard, CEO Biolipox AB, c/o Healthcap Sturegatan 34 Stockholm, Suède Tel: 46 70 975 98 63

Visit website http://www.orexo.com

26/04/2001

Sofinnova Partners, one of the leading French and European venture capital
firms specializing in information technologies and life sciences, has raised EUR
330 million for its new Sofinnova Capital IV fund. The initial objective of EUR
230 million was surpassed because of strong demand from investors in previous
Sofinnova funds as well as from new investors.


Important investors in previous funds, such as JP Morgan, AGF, HarbourVest
Partners, Swiss Re, Fondinvest, and Dresdner Kleinwort Benson, have also
invested in Sofinnova Capital IV. It has also attracted new investors, both
financial (including PartnersGroup and LGT) and industrial (IBM, Dow Chemical
and others) as well as private investors, including founders of companies
financed by Sofinnova Partners.


This is the largest amount raised by an independent European venture capital
fund for many months and takes place in a market environment that is not exactly
favorable. In 1998, when it closed its previous fund, Sofinnova Capital III,
Sofinnova Partners had raised EUR 120 million, of which 60% had been invested as
of March 31, 2001 in 30 companies.


According to Jean-Bernard Schmidt, Managing Partner of Sofinnova Partners,
“the success of this fund raising exercise is a witness to investors’ confidence
in Sofinnova Partners, and rewards the professionalism and dedication of our
management team. For a number of years, we have built innovative companies by
working alongside their founders. A high proportion of our investment selections
have met with success. This new fund gives us the resources to continue
investing in promising European companies in both the life sciences and network
technologies fields. It strengthens our position as a leading European venture
capital player”.


A targeted and selective investment strategy


– Sofinnova Capital IV aims to invest EUR 8-12 million each in 30 new
companies, spread over several rounds of financing.


– Investments will be split evenly between the two sectors in which Sofinnova
Partners has specialized since 1989: information technology and life sciences.


– In line with Sofinnova Partners’ strategy, the new fund will concentrate
its investments in ambitious projects and companies being formed or in their
early stage of development.


– In the information technology field, Sofinnova Partners will focus on
financing projects related to network technologies, a market expected to attract
two thirds of all information technology investments between now and 2004.


– In life sciences, Sofinnova Capital IV will continue to concentrate its
investments in two vital fields: biopharmaceutical projects directed at major
pathologies such as central nervous system disorders, infectious diseases and
cancer, and medical instrumentation projects that are likely to set new
international standards.


– Sofinnova Capital IV will be 50% invested in France, 35% in other European
countries and 15% in the US.


Six investments have already been made


Sofinnova Partners has already made six investments on behalf of the new
fund.


. Four are in the life sciences sector:


->Neuro 3D, a French company developing compounds for the treatment of
disorders of the central nervous system, which Sofinnova Partners financed at
the seed stage and for which it was co-leader of the first financing round in
November 2000 (EUR 1.3 million).


->Cellzome, a German company in which Sofinnova Partners invested EUR 5.6
million in February 2001, specialized in proteomics and a spin-off from the
prestigious EMBL research center in Heidelberg.


->Biolipox, a Swedish company specialized in the discovery and development
of new therapeutic compounds for use in the treatment of respiratory diseases.
Sofinnova Partners was the co-leader for the first financing round, which raised
EUR 2.3 million in March 2001.


->David Pharmaceuticals, a US company specialized in the development of
new therapeutic compounds for use in the treatment of memory disorders.
Sofinnova Partners invested EUR 3.3 million as co-lead investor with Sofinnova
Ventures in San Francisco.


. Two investments are in the information technologies field:


->E-mail Vision, a French company that provides software platforms for
implementing direct marketing campaigns on the Internet. Sofinnova partners
invested EUR 3.5 million in March 2001 as leader of a new financing round.


->T-Source, a new seed fund specialized in telecommunications and formed
by I-source Gestion. Sofinnova Partners invested EUR 2 million in March 2001.
Sofinnova Partners, which traces its origins back to 1972, is managed by a
close-knit team of seven investment specialists with complementary skills, drawn
from extremely diverse backgrounds and organized into two specialized groups
(life sciences and information technology). This team draws on a quality
European network of partner-investors and on its natural partner in the US,
Sofinnova Ventures in San Francisco, for its international development. It
currently manages EUR 500 million of assets.

26/04/2001

Sofinnova Partners, un des leaders français et européen du capital-risque
spécialisé dans les technologies de l’information et les sciences de la vie, a
levé 330 millions d’euros pour son nouveau fonds Sofinnova Capital IV.
L’objectif initial de la société, qui était de réunir 230 millions d’euros, a
été largement dépassé, compte tenu de la forte demande des investisseurs de ses
précédents fonds et, également, de nouveaux investisseurs.


Parmi les investisseurs de Sofinnova Capital IV, plusieurs investisseurs
importants des fonds précédents ont réinvesti : JP Morgan, AGF, HarbourVest
Partners, Swiss Re, Fondinvest, Dresdner Kleinwort Benson. Mais Sofinnova
Capital IV compte également de nouveaux investisseurs financiers (PartnersGroup,
LGT…) et industriels (IBM, Dow Chemical…) ainsi que des investisseurs privés,
dont plusieurs fondateurs d’entreprises financées par Sofinnova Partners.


Il s’agit du montant le plus élevé réuni par un capital-risqueur indépendant
en Europe depuis de longs mois, dans un environnement de marché pourtant peu
favorable. En 1998, lors de la clôture de son précédent fonds, Sofinnova Capital
III, Sofinnova Partners avait levé 120 millions d’euros, dont 60% ont été
investis au 31 mars 2001 dans trente entreprises.


Jean-Bernard Schmidt, Président de Sofinnova Partners, a déclaré : “Le succès
de cette levée de fonds, témoigne de la confiance des investisseurs à notre
égard, récompense le professionnalisme et le sérieux de notre équipe. Nous
sommes, depuis de nombreuses années, des bâtisseurs d’entreprises innovantes aux
côtés de leurs créateurs. Nos choix d’investissement sont, dans une proportion
élevée, couronnés de succès. Ce nouveau fonds nous donne les ressources
nécessaires pour continuer à investir dans des entreprises européennes
prometteuses, tant dans les sciences.de la vie que dans les technologies de
réseaux. Il nous conforte dans notre position d’acteur européen incontournable
du capital-risque”.


Une stratégie d’investissements ciblée et sélective


– L’objectif de Sofinnova Capital IV est d’investir dans trente nouvelles
entreprises pour des montants cumulés de 8 à 12 M d’euros par entreprise, en
plusieurs tours de financement.


– Les investissements se répartiront de façon équitable entre les deux
secteurs dans lesquels Sofinnova Partners s’est spécialisé depuis 1989 :
technologies de l’information et sciences de la vie. ¨ Dans le droit fil de la
stratégie de Sofinnova Partners, le nouveau fonds concentrera ses
investissements sur des projets d’amorçage, de création et de post-création
d’entreprises.


– Dans le domaine des technologies de l’information, Sofinnova Partners
financera en priorité des projets liés aux technologies de réseaux, un marché
appelé à capter les deux tiers des investissements en technologies de
l’information d’ici 2004.


– En sciences de la vie, Sofinnova Capital IV continuera à se concentrer sur
deux domaines essentiels : la biopharmacie visant des pathologies majeures comme
les maladies du système nerveux central, les maladies infectieuses ou le cancer
et des projets d’instrumentation médicale susceptibles de devenir des standards
internationaux.


– Sofinnova Capital IV sera investi à hauteur de 50% en France, de 35% dans
les autres pays d’Europe et 15% aux Etats-Unis.


Six investissements déjà réalisés


Dans le cadre de ce nouveau fonds, l’équipe de Sofinnova Partners a déjà
procédé à six investissements.


. Quatre d’entre eux concernent les sciences de la vie :


-> Neuro 3D, entreprise française développant des molécules dans le
domaine des maladies du système nerveux central, dont elle a financé l’amorçage
et a été co-leader du premier tour de table en novembre 2000 (1.3M d’euros).


->Cellzome, entreprise allemande de protéomique issue du prestigieux
centre EMBL de Heidelberg, dans laquelle elle a investi 5.6M d’euros en Février
2001


->Biolipox, entreprise suédoise spécialisée dans la découverte et le
développement de nouvelles molécules thérapeutiques dans les maladies
respiratoires dans laquelle elle est intervenue en tant que co-leader du premier
tour de table à hauteur de 2.3 M d’euros en mars 2001


->David Pharmaceuticals, entreprise américaine spécialisée dans le
développement de nouvelles molécules thérapeutiques pour le traitement des
pathologies de la mémoire, dans laquelle elle est intervenue à hauteur de 3,3 M
d’euros, en tant qu’investisseur co-leader avec Sofinnova Ventures à San
Fransisco.


. Deux autres investissements concernent les technologies de l’information :


->e-mail Vision, entreprise française fournissant une plate-forme
logicielle pour la mise en œuvre de campagnes de marketing direct sur Internet,
dans laquelle elle a investi 3.5M d’euros en mars 2001 en tant que leader d’un
nouveau tour de financement


->T-Source, nouveau fonds d’amorçage dans les télécommunications
d’I-source gestion, dans lequel elle a investi 2M d’euros en mars 2001


Sofinnova Partners, dont l’origine de l’activité remonte à 1972, est dirigée
par une équipe de 7 investisseurs solidaires et complémentaires issus d’horizons
extrêmement divers et organisés en deux pôles spécialisés (sciences de la vie et
technologies de l’information). Cette équipe s’appuie, pour son développement
international, sur un réseau européen de partenaires-investisseurs de premier
plan et pour les Etats-Unis sur son partenaire naturel, Sofinnova Ventures à San
Fransisco. L’équipe gère actuellement 500 M d’euros de fonds actifs.

04/04/2001

E-Mail Vision lève 7,25 millions d’euros pour son 3ème tour de table


La société se donne les moyens de renforcer son leadership sur le marché
européen du e-mail marketing externalisé


E-Mail Vision, le leader européen des solutions e-mail marketing, vient de
boucler un des plus importants tour de table de ce début d’année 2001. Deux
nouveaux investisseurs, SOFINNOVA PARTNERS et la SPEF ont rejoint les
investisseurs historiques, ABN AMRO CAPITAL et APOLLO INVEST pour apporter
ensemble plus de 7 millions d’euros. Cette injection de capital permettra à
E-Mail Vision d’atteindre la rentabilité et de consolider sa position de leader
sur le marché européen. Six millions d’euros ont déjà été injectés dans le
capital de cette entreprise depuis sa fondation, en mai 1999.


” Le e-mail marketing, lorsqu’il est réalisé par des spécialistes, constitue
aujourd’hui un canal de marketing à fort retour sur investissement pour les
entreprises “, déclare Nick Heys, fondateur et CEO d’E-Mail Vision. ” Pionniers
sur le marché Européen, nous avons mis en place les infrastructures
technologiques les plus performantes et une équipe de professionnels des plus
qualifiée en Europe. Cette levée de fonds nous donne les moyens d’affirmer notre
position de leader sur le marché européen “, ajoute Nick Heys.


E-Mail Vision met à disposition de ses clients une application 100 % web et
une infrastructure technologique leur permettant de gérer, personnaliser et
assurer le suivi de leurs campagnes de permission e-mail marketing. Il offre
également une gamme complète de services de production et de conseil pour les
sociétés souhaitant un service global.


” Nous sommes ravis d’accueillir SOFINNOVA PARTNERS et la SPEF au sein de
notre capital et conseil de direction. Ces investisseurs prestigieux nous
apportent leur expérience et leur carnet d’adresses que nous comptons utiliser
pour démultiplier l’essor de notre activité. Nous sommes également heureux de la
confiance qu’ABN AMRO et APOLLO INVEST ont décidé de nous renouveler “, explique
Nick Heys.


Alain Rodermann, partenaire associé de SOFINNOVA PARTNERS (sofinnova.social-unit.fr) explique pour sa part : ”
Nous sommes fiers d’ajouter E-Mail Vision à notre portefeuille d’investissements
et allons nous employer à aider activement l’équipe E-Mail Vision à bâtir une
société solide sur ce nouveau marché. Notre choix d’investissement nous a été
largement dicté par la confiance que nous accordons à la fois au business model,
à la technologie et aux managers qui composent la société. ”


Marco de Alfaro, directeur associé de SPEF e-FUND (www.spef.fr) ajoute quant à lui : ” Nous sommes
très enthousiastes concernant notre investissement dans E-Mail Vision qui
s’inscrit dans plusieurs tendances que nous observons, comme le marketing direct
et l’ASP. Nous pensons que cette entreprise est positionnée de façon unique pour
bénéficier en premier de l’énorme croissance de la demande des sociétés
européennes en matière de technologies et de services d’e-mail marketing.”


Bernard Louis Roques, partenaire associé de ABN AMRO VENTURE commente : ”
E-Mail Vision dispose désormais d’une solide plate-forme d’investisseurs et des
moyens qui lui permettront de construire des barrières aux nouveaux entrants sur
ce marché tout en y renforçant sa position de leadership. “. Enfin, Laurent
Asscher, CEO d’APOLLO INVEST conclut : ” Rien ne s’oppose plus maintenant à ce
qu’E-Mail Vision rafle la mise sur un marché de plus en plus globalisé. “


La société E-Mail Vision a été conseillée par Valluet Achache & Associés
et ABN Amro Corporate Finance.


A propos d’E-Mail Vision Créée en France en mai 1999, E-Mail Vision (www.emailvision.com) propose une
plate-forme technologique sous forme d’ASP (Application Service Provider) ainsi
que des services complets de gestion de campagnes de marketing direct par
e-mails. La solution E-Mail Vision permet aux entreprises de fidéliser leurs
clients à des coûts exceptionnellement bas par rapport aux méthodes de marketing
direct classiques. A l’opposé du ” Spam “, le ” permission e-mail marketing ”
consiste à envoyer des campagnes par e-mail à des individus qui ont
préalablement donné leur accord. Ces campagnes peuvent prendre la forme de
newsletters, d’alertes ou d’offres commerciales personnalisées selon le profil
du client. E-Mail Vision dispose d’une solide base de clients dont MTV, Médecins
sans Frontières, Le Club des Créateurs de Beauté (L’Oréal), Louis Vuitton,
Chapitre.com, Bouygues Telecom, e-TF1, Dell et Décathlon. E-Mail Vision a en
outre noué des partenariats commerciaux avec des agences Web et de marketing
direct tels que Publicis Dialog, Direct One et Icon Medialab.


Visit website http://www.emailvision.com

04/04/2001

E-Mail Vision raises 7.25 Million Euros in series C round Company now
positioned for European leadership in outsourced e-mail marketing services


E-Mail Vision (www.emailvision.com)
the leading European e-mail marketing services company with headquarters in
Paris, France has raised over 7 million Euros in its series C round. New
investors SOFINNOVA PARTNERS and SPEF joined current investors ABN AMRO CAPITAL
and APOLLO INVEST in the private placement. The company, founded in May 1999 by
Nick Heys, stated that the capital will see it through to profitability and
enable it to consolidate its leadership position in the European marketplace.
The company has previously raised over 6 Million Euros.


“E-mail marketing, when done right, is now a proven high return on investment
channel for marketers”, declared Nick Heys, Founder & CEO of E-Mail Vision.
As first movers, we have built the most advanced technology infrastructure and
most experienced professional services team in Europe. With this new round of
funding we are now uniquely positioned for leadership in the European market”.


E-Mail Vision offers clients a powerful web based application and technology
infrastructure to manage, personalise, deliver and track permission e-mail
marketing campaigns. It also offers a complete range of production, consulting
and database services for companies seeking a full service solution.


“We are delighted to add SOFINNOVA PARTNERS and SPEF to our investor base and
board of directors. These prestigious investors bring a wealth of experience and
contacts which we intend to leverage in building our business. We are also
pleased that APOLLO INVEST and ABN AMRO re-invested in this round showing
continued commitment to our business and management team” said Nick Heys.


Alain Rodermann, partner at SOFINNOVA PARTNERS (sofinnova.social-unit.fr) said “we are pleased to
have added E-Mail Vision to our investment portfolio and look forward to
supporting the management team in building a great company in this new market.
Our investment decision was driven by our belief in the E-Mail Vision business
model, technology and experienced management team”.


Marco de Alfaro, director of SPEF e-FUND (www.spef.fr) added. “We are very excited about our
investment in E-Mail Vision, which fits with several key trends that we see,
such as direct marketing and ASP. We believe this company is uniquely positioned
to benefit from the huge growth in demand for outsourced e-mail marketing
systems and services in Europe”.


Bernard Louis Roques, partner at ABN AMRO VENTURE said “E-Mail Vision now has
a strong investor base and the means to continue building barriers to entry and
maintain its leadership position in Europe”.


Laurent Asscher, CEO of APOLLO INVEST added “E-Mail Vision is now extremely
well prepared to compete and win in an increasingly global marketplace”. E-Mail
Vision was assisted by ABN Amro Corporate Finance and Cabinet Valluet-Achache
& Associés in completing this C Round.


Visit website http://www.emailvision.com

16/01/2001

Bernard Gilly, former President and Chief Executive Officer of Transgene, is joining Denis Lucquin and Antoine Papiernik as partner in the Life Sciences team of Sofinnova Partners.


Sofinnova Partners, a venture capital pioneer in France, is a European leader in the areas of life sciences and communication technologies.


Bernard Gilly, aged 44, is an agronomist, a Doctor of Economics and holds a MBA from INSEAD. He began his career in 1980 at Inra and Ifremer before joining Pasteur Mérieux as Associate Director of Research in 1988. Appointed Managing Director of Transgene in 1992, he completely overhauled the company and rapidly made it a world leader in gene therapy, before successfully launching it simultaneously onto the Nouveau Marché of the Paris Stock Exchange and the New York NASDAQ in March 1998. Simultaneously, from 1994 to July 1997, Bernard Gilly was VP Research and Development of BioMérieux, the major stockholder of Transgene. He left Transgene at the end of November 2000 to join Sofinnova Partners. He is also a member of the Governing Boards of INSERM (French National Medical Research Institute) and the Ecole Normale Supérieure de Lyon. Co-founder of France-Biotech, Bernard Gilly has been extensively involved in the emergence and development in France of new companies using advanced technologies: member of the Steering Committee of Croissance Plus, he participates in the Boards of Wavecom (a French company quoted on the Nouveau Marché, specializing in telecom integrated modules) and HighDeal (start-up created in February 2000, specializing in the management of value-added chain on the Internet). He is also President and co-founder of WebSurg, a start-up specializing in education and e-training of surgeons and para-surgical professions on the Internet.


“I am very happy today to be joining a skilled team esteemed and respected for its professionalism and involvement with start up companies” said Bernard Gilly. “I will focus my efforts on the early discovery of innovative companies, so as to help them establish their position and quickly develop as leaders in their own field”.


Jean-Bernard Schmidt, President of Sofinnova Partners, stated:”The arrival of Bernard Gilly in our team will considerably strengthen our position on a European level. His experience as a researcher, then manager and developer of one of the finest European biotechnology companies, will be of great value to us in enhancing our ability to identify and facilitate the germination of the best company projects in the Life Sciences sector”.


Based in Paris, the Sofinnova Partners team now consists of 7 partners, managing close to 3 billion French francs. Regarding Life Sciences, Sofinnova Partners is an early stage investor in biopharmaceutical and medical devices. Sofinnova Partners has been in particular a founding investor in companies such as GENSET, CEREP, NICOX, ACTELION and NOVUSPHARMA. Its investments in Information Technologies have essentially concerned Internet and telecoms, application software and micro-electronics. Since 1996, Sofinnova Partners has made 50 investments, including 31 as lead investor. It currently sits on the boards of 27 of them and hence continues to provide active support. Sofinnova Partners evaluates each year between 1000 and 2000 new investment proposals.